Develops investigational therapies that target misfolded proteins for neurodegenerative and rare amyloid diseases, working with pharmaceutical companies on clinical development and licensing.
10-K for FY2025, filed Feb 27, 2026Prothena Corporation plc (“Prothena” or the “Company”) is a late-stage clinical biotechnology company with expertise in protein…View ↗
Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a…View ↗
Our near-term plan is to continue to support our active clinical programs which are all partnered with large pharmaceutical companies…View ↗
Pharmaceutical partners pay upfront and option fees, for research and manufacturing services, and milestone payments when programs reach clinical, regulatory or sales targets; agreements may also bring royalties. Prothena also receives payment for intellectual property and related rights.
10-K for FY2025, filed Feb 27, 2026The Company’s collaboration revenue includes revenue recognized under the Company’s Collaboration Agreement with BMS as well as revenue…View ↗
The terms of license, option and collaboration agreements entered into typically include payment of one or more of the following…View ↗
Revenue is recognized only when the Company satisfies an identified performance obligation by transferring a promised good or service to a…View ↗
The Company generally classifies each of its milestones into one of three categories: (i) clinical milestones; (ii) regulatory and…View ↗
At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, the Company evaluates…View ↗
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by product or service ↗$9.7M
10-K for FY2025, filed Feb 27, 2026
$9.7M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Collaboration revenue
|
99%
FY2022: 26%
|
Collaboration revenue, FY2025
$9.6M Sources
|
|
|
Revenue from license and intellectual property
Licensed
|
0.5%
FY2022: 74%
|
Revenue from license and intellectual property, FY2025
$50K Sources
|
Licensed |
Drug-company partners work with Prothena through licensing and collaboration agreements, including Roche and Bristol Myers Squibb; Novo Nordisk acquired its ATTR amyloidosis business.
10-K for FY2025, filed Feb 27, 2026Our robust discovery engine generates new targets and compounds that have the potential to treat unmet medical needs. For investigational…View ↗
As we move our drug candidates through development toward regulatory approval, we will evaluate several strategic options for…View ↗
Coramitug (formerly PRX004) - Rentschler Biopharma SE (“Rentschler”) manufactured clinical supplies of our drug candidate coramitug for our…View ↗
Revenue is recognized only when we satisfy an identified performance obligation by transferring a promised good or service to a customer.…View ↗
The Company’s collaboration revenue includes revenue recognized under the Company’s Collaboration Agreement with BMS as well as revenue…View ↗
No. It lost $244.1M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$16.5MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
Shrinking. Revenue fell 95% in 4 years, from $200.6M in FY2021 to $9.7M in FY2025, about 53% a year.
Clinical portfolio
The older report included company-owned clinical programs in AL amyloidosis and Alzheimer’s; the latest describes its active clinical portfolio as partnered, with wholly owned work focused on research and preclinical development.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 27, 2026
Loading...